tiprankstipranks
Advertisement
Advertisement
Cartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation
PremiumCompany AnnouncementsCartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation
2M ago
RNAC’s Descartes-08 Moves Toward Phase 2 in Rare Muscle Disease: What Investors Should Watch
Premium
Company Announcements
RNAC’s Descartes-08 Moves Toward Phase 2 in Rare Muscle Disease: What Investors Should Watch
3M ago
Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
Premium
The Fly
Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
3M ago
Cartesian Therapeutics announces employment inducement grants
PremiumThe FlyCartesian Therapeutics announces employment inducement grants
4M ago
Cartesian Therapeutics Outlines 2026 Outlook and Trial Progress
Premium
Company Announcements
Cartesian Therapeutics Outlines 2026 Outlook and Trial Progress
5M ago
Cartesian Therapeutics highlights recent progress, outlines 2026
Premium
The Fly
Cartesian Therapeutics highlights recent progress, outlines 2026
5M ago
Strategic Realignment Boosts Cartesian Therapeutics’ Prospects: Gil Blum Issues Buy Rating
PremiumRatingsStrategic Realignment Boosts Cartesian Therapeutics’ Prospects: Gil Blum Issues Buy Rating
6M ago
Cartesian Therapeutics price target raised to $44 from $42 at BTIG
Premium
The Fly
Cartesian Therapeutics price target raised to $44 from $42 at BTIG
6M ago
Cartesian Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
Cartesian Therapeutics Reports Q3 2025 Financial Results
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100